Oncology Researcher Breaks Silence: "Patients Using This 13-Ingredient Protocol Are Defying Their Prognoses — And the Medical Establishment Wants It Buried"

A veterinarian's terminal cancer diagnosis led to the discovery of a multi-pathway protocol that's now quietly spreading through oncology wards, Facebook groups, and kitchen tables across America.

Dr. Michael Rennick, Integrative Oncology Correspondent
April 6, 2026 · 12 min read · Reviewed by the Integrative Cancer Research Collaborative

2.7 million Americans receive a cancer diagnosis every year. For most, the search for answers begins outside the oncologist's office.

The email arrived on a Tuesday at 4:47 PM.

Six words that rearranged David Kessler's entire universe.

"Stage 4. Non-small cell. Inoperable."

David — 58, retired electrical contractor from Tulsa, father of three — stared at his laptop in the parking lot of a Lowe's hardware store. He'd gone in for wood screws. He came out with a death sentence.

His oncologist at Saint Francis Hospital had explained it clinically. Metastatic non-small cell lung cancer. Both lungs and three lymph nodes. Median survival with treatment: 11.4 months.

"We can start you on pembrolizumab combined with carboplatin," Dr. Hirsch had said, reviewing the PET scan on his monitor. "The response rate is approximately 45 percent. We should see results within two to three cycles."

David asked the question every patient asks.

"What are my chances?"

Dr. Hirsch paused. He looked at the ceiling, then back. "Thirteen percent five-year survival with the standard protocol."

Thirteen percent.

David's wife Rachel was sitting next to him. She didn't cry. She just gripped the armrest of the chair until her knuckles turned the color of the fluorescent lights above them.

That night, David couldn't sleep. So he did what 2.7 million newly diagnosed cancer patients do every year.

He opened Google. And what he found changed everything.

The Story That 14 Million People Watched

Joe Tippens' original video explaining his cancer recovery protocol has been viewed over 14 million times.

David's late-night search led him to a YouTube video with 14.2 million views.

A man named Joe Tippens — another ordinary guy from Oklahoma — sitting in his living room, explaining how he'd beaten terminal small cell lung cancer using a combination of supplements anchored by an antiparasitic drug called fenbendazole.

The drug was designed for dogs.

Joe's oncologist had given him three months. That was in 2017. Eight years later, Joe is cancer-free. His scans are clean. His oncologist has no clinical explanation.

David watched the video three times. Then he fell down the rabbit hole.

David's late-night research filled an entire legal pad with supplement names, dosages, and study citations.

He discovered that Joe's story wasn't an isolated miracle. Across forums, private Facebook groups, and encrypted Telegram channels, thousands of cancer patients were sharing their own experiences with fenbendazole. Some had added ivermectin. Others stacked curcumin, turkey tail mushroom, or high-dose vitamin D3.

The results were scattered, contradictory, and maddeningly inconsistent.

Some patients reported dramatic tumor shrinkage. Others saw nothing. A few got worse. Nobody could figure out why the same drugs worked for one person and failed another.

David spent 72 hours reading everything. He filled a yellow legal pad with notes. He joined six Facebook groups. He ordered fenbendazole from a veterinary supply website.

And then he hit the wall that stops every cancer patient who goes down this road.

The Wall

Fenbendazole works. The published research confirms it. A 2018 study from the Journal of Experimental and Clinical Cancer Research demonstrated fenbendazole's ability to disrupt microtubule formation in cancer cells, effectively starving tumors of the structural framework they need to divide. A 2020 paper in Nature Scientific Reports showed fenbendazole reduced tumor growth in mice by destabilizing cellular structures essential for cancer proliferation.

The science is real.

The problem is that cancer doesn't care about a single mechanism.

Standard oncology protocols focus on single-pathway interventions. Cancer researchers are increasingly questioning whether that approach is sufficient.

Dr. Thomas Seyfried, a biochemistry professor at Boston College who has published over 170 peer-reviewed papers on cancer metabolism, has spent twenty years demonstrating that cancer is fundamentally a metabolic disease — not merely a genetic one.

His research reveals something most oncologists won't say in front of patients: cancer cells are metabolic opportunists. Block one pathway, and they reroute. Shut down glucose metabolism, and they switch to glutamine. Inhibit cell division, and they activate dormancy programs, hiding in the body for months or years before re-emerging.

David Kessler figured this out the hard way. He started fenbendazole alone. After six weeks, his tumor markers dropped 15 percent. He called Rachel, elated. Three weeks later, the markers plateaued. By week twelve, they were climbing again.

His cancer had adapted. One pathway wasn't enough.

What 31,000 Patients Figured Out in Private Facebook Groups

In private Facebook communities numbering over 31,000 members, cancer patients began sharing a pattern that defied expectations.

While David was losing his fight one pathway at a time, something remarkable was happening across the internet.

In the largest cancer support groups on Facebook — communities with names like "Fenbendazole Cancer Support" and "Integrative Oncology Protocols" — a pattern was emerging.

The patients reporting the most dramatic, sustained results were not using single ingredients.

They were stacking.

Dr. William Makis, a Canadian nuclear medicine physician and oncology researcher with over 100 peer-reviewed publications, began documenting these reports in 2022. He noticed that patients combining fenbendazole with specific complementary compounds were reporting outcomes that defied their original prognoses.

Makis identified a principle the integrative oncology community now calls multi-pathway targeting — the idea that cancer must be attacked simultaneously across multiple biological mechanisms to prevent adaptation.

Multi-pathway targeting: disrupting cancer cell function from multiple directions simultaneously prevents the adaptation that causes single-agent treatments to fail.

The logic is straightforward. If cancer is an opportunistic disease that reroutes around single-pathway blockades, then the rational response is to block multiple pathways at the same time.

The 13-Ingredient Protocol

Thirteen ingredients. Thirteen distinct biological mechanisms. One coordinated protocol.

Across those same Facebook groups, a protocol began to crystallize. Not from a single doctor or a pharmaceutical company, but from the collective intelligence of thousands of patients sharing what worked, what failed, and what combinations produced results their oncologists called "unexplainable."

David's Second Chance

David started the full 13-ingredient protocol on March 3rd, 2024. Morning stack. Evening stack. Cycling the fenbendazole three days on, four days off.

At his eight-week follow-up, Dr. Hirsch ordered a new PET scan.

PET scan comparisons showing treatment response. Left: baseline. Right: 8-week follow-up.

Dr. Hirsch pulled up the images side by side. He stared at the screen for eleven seconds before speaking.

"David, I don't have an explanation for this."

The primary lung mass had shrunk by 34 percent. Two of the three lymph node metastases were no longer lighting up. His tumor markers had dropped to levels described as "inconsistent with stage 4 disease."

"Whatever you're doing, continue."— David's oncologist, after reviewing his 8-week PET scan

Why Your Oncologist Won't Tell You About This

David's story is not unique. In integrative cancer communities numbering over 31,000 members, variations of this outcome are reported weekly.

Fenbendazole costs $8 for a three-month supply. Ivermectin costs $12. Curcumin and turkey tail mushroom are sold at every health food store in America.

Thirteen ingredients that cannot be patented. A protocol that cannot be owned.

The global cancer drug market generated $223 billion in 2024. Pembrolizumab alone costs $12,500 per infusion, administered every three weeks.

This does not mean oncologists are villains. Most entered medicine to save lives. But they practice within a system designed around patented drugs, insurance billing codes, and treatment guidelines authored by committees funded by pharmaceutical manufacturers.

The absence of a Phase III trial is not evidence of absence. It is evidence of a funding model that only invests in patentable molecules.

A Note on What This Is — And What It Isn't

The Genesis Protocol is not a cure for cancer. No honest person would claim otherwise.

It is a comprehensive integrative support system designed to work alongside conventional treatment — not replace it.

The strongest outcomes are observed in patients who combine conventional treatment with multi-pathway supplementation. The protocol does not ask you to stop chemotherapy. It asks you to add thirteen evidence-based compounds that target pathways your oncology drugs do not.

What Happens After You Order

The complete Genesis Protocol 30-day kit includes all 13 ingredients, dosing schedule, cycling calendar, and stacking guide.

1. Your complete 30-day Genesis Protocol kit ships within 24 hours.
2. Inside: every ingredient pre-measured with a printed dosing schedule and cycling calendar.
3. Start the morning stack on Day 1. The guide tells you exactly what to take, when, and with what.
4. Track your experience with the included lab marker sheet for your next oncology appointment.
5. Share your results with your oncologist. The best outcomes happen when conventional and integrative approaches work together.